Analysts forecast that LeMaitre Vascular Inc (NASDAQ:LMAT) will announce sales of $28.10 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for LeMaitre Vascular’s earnings, with estimates ranging from $27.89 million to $28.22 million. LeMaitre Vascular reported sales of $24.17 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 16.3%. The firm is scheduled to issue its next quarterly earnings results on Thursday, October 3rd.

According to Zacks, analysts expect that LeMaitre Vascular will report full-year sales of $116.10 million for the current fiscal year, with estimates ranging from $115.90 million to $116.32 million. For the next financial year, analysts forecast that the company will report sales of $123.78 million, with estimates ranging from $122.10 million to $124.80 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Wednesday, July 24th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.02. The firm had revenue of $29.48 million for the quarter, compared to analyst estimates of $28.90 million. LeMaitre Vascular had a net margin of 16.72% and a return on equity of 13.15%. The business’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.43 EPS.

Several analysts recently issued reports on LMAT shares. Lake Street Capital increased their price target on shares of LeMaitre Vascular from $27.00 to $34.00 and gave the stock a “hold” rating in a research report on Thursday, July 25th. Barrington Research restated an “outperform” rating and issued a $37.00 target price (up previously from $32.00) on shares of LeMaitre Vascular in a research report on Thursday, July 25th. ValuEngine upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Monday, July 22nd. First Analysis upgraded shares of LeMaitre Vascular from a “neutral” rating to an “outperform” rating and raised their target price for the company from $29.00 to $37.00 in a research report on Thursday, July 25th. Finally, BidaskClub upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Friday, July 19th. Three analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $35.33.

Shares of NASDAQ LMAT traded down $0.57 during trading hours on Friday, hitting $31.00. 9,129 shares of the stock were exchanged, compared to its average volume of 144,423. The firm has a market cap of $631.93 million, a P/E ratio of 37.00, a PEG ratio of 3.70 and a beta of 1.15. The firm has a fifty day moving average of $30.34. LeMaitre Vascular has a 1-year low of $21.79 and a 1-year high of $38.99.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 5th. Stockholders of record on Wednesday, August 21st will be paid a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a dividend yield of 1.10%. The ex-dividend date is Tuesday, August 20th. LeMaitre Vascular’s payout ratio is currently 40.48%.

In related news, Director Lawrence J. Jasinski sold 5,000 shares of LeMaitre Vascular stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $32.00, for a total transaction of $160,000.00. Following the completion of the transaction, the director now owns 10,833 shares of the company’s stock, valued at $346,656. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael H. Thomas sold 15,000 shares of LeMaitre Vascular stock in a transaction on Friday, August 9th. The stock was sold at an average price of $32.10, for a total transaction of $481,500.00. Following the transaction, the director now directly owns 15,000 shares of the company’s stock, valued at approximately $481,500. The disclosure for this sale can be found here. Insiders have sold 98,037 shares of company stock valued at $3,310,555 in the last three months. 19.60% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its stake in LeMaitre Vascular by 1.5% in the fourth quarter. Bank of New York Mellon Corp now owns 256,990 shares of the medical instruments supplier’s stock worth $6,075,000 after acquiring an additional 3,841 shares during the period. Geode Capital Management LLC boosted its position in LeMaitre Vascular by 11.0% in the fourth quarter. Geode Capital Management LLC now owns 200,496 shares of the medical instruments supplier’s stock valued at $4,739,000 after buying an additional 19,828 shares during the last quarter. Bank of America Corp DE boosted its position in LeMaitre Vascular by 162.1% in the fourth quarter. Bank of America Corp DE now owns 23,031 shares of the medical instruments supplier’s stock valued at $544,000 after buying an additional 14,243 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its position in LeMaitre Vascular by 373.8% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 5,629 shares of the medical instruments supplier’s stock valued at $133,000 after buying an additional 4,441 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan purchased a new stake in LeMaitre Vascular in the fourth quarter valued at approximately $106,000. 78.35% of the stock is owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

See Also: Mutual funds are not immune from market timing

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.